Legend Biotech(DE:9LB)
€18.50-2.90 (-11.90%)
DE:9LB
Legend Biotech stock forecast
€18.50
At close:-2.90 (-11.90%)
Legend Biotech (9LB) Stock Forecast & Price Target
1 Followers
9LB Analyst Ratings
Moderate Buy
6Buy4Hold0Sell
Based on 10 analysts giving stock ratings to Legend Biotech in the past 3 months
9LB Stock 12 Month Forecast
Average Price Target
EUR 37.87▲(104.73% Upside)Based on 10 Wall Street analysts offering 12 month price targets for Legend Biotech in the last 3 months. The average price target is EUR 37.87 with a high forecast of EUR 58.20 and a low forecast of EUR 21.49. The average price target represents a 104.73% change from the last price of EUR 18.50.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 58.20
AverageEUR 37.87
LowEUR 21.49
Highest Price TargetHighestEUR 58.20Average Price TargetEUR 37.87Lowest Price TargetLowestEUR 21.49
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Etzer Darout | Barclays | EUR 60.88→EUR 54.62 | buy | 195.22%Upside | Reiterated | 11/11/26 | ||
| Mitchell Kapoor | H.C. Wainwright | EUR 58.20 | buy | 214.58%Upside | Reiterated | 11/11/26 | ||
| Kostas Biliouris | Oppenheimer | EUR 35.81→EUR 22.38 | hold | 20.99%Upside | Reiterated | 11/11/26 | ||
| Terence Flynn | Morgan Stanley | EUR 38.50 | buy | 108.11%Upside | Reiterated | 11/11/26 | ||
| Ziyi Chen | Goldman Sachs | EUR 34.10→EUR 30.45 | buy | 64.60%Upside | Reiterated | 11/11/26 | ||
| Leonid Timashev | RBC Capital | EUR 50.14→EUR 44.77 | buy | 141.99%Upside | Assigned | 11/10/26 | ||
| Edward Tenthoff | Piper Sandler | EUR 57.30 | buy | 209.74%Upside | Reiterated | 11/05/26 | ||
| Ashwani Verma | UBS | EUR 21.49 | hold | 16.15%Upside | Reiterated | 10/27/26 | ||
| Jessica Fye | J.P. Morgan | EUR 31.34→EUR 29.55 | hold | 59.71%Upside | Reiterated | 10/09/26 | ||
| Yaron Werber | TD Cowen | EUR 25.97→EUR 21.49 | hold | 16.15%Upside | Assigned | 08/12/26 | ||
| Asthika Goonewardene | Leerink Partners | EUR 62.67 | buy | 238.78%Upside | Reiterated | 03/13/26 | ||
| James Shin | Deutsche Bank | EUR 53.72 | buy | 190.38%Upside | Reiterated | 03/09/26 | ||
| Qize Ding | Rothschild & Co Redburn | EUR 74.31→EUR 21.49 | hold | 16.15%Upside | Downgraded | 02/12/26 | ||
| Eric Schmidt FCA | Cantor Fitzgerald | EUR 67.15→EUR 66.26 | buy | 258.14%Upside | Reiterated | 12/17/25 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Etzer DaroutBarclays | BuyReiteratedEUR 60.88→EUR 54.62 | 11/11/26 | 195.22%Upside | ||
| Mitchell KapoorH.C. Wainwright | BuyReiteratedEUR 58.20 | 11/11/26 | 214.58%Upside | ||
| Kostas BiliourisOppenheimer | HoldReiteratedEUR 35.81→EUR 22.38 | 11/11/26 | 20.99%Upside | ||
| Terence FlynnMorgan Stanley | BuyReiteratedEUR 38.50 | 11/11/26 | 108.11%Upside | ||
| Ziyi ChenGoldman Sachs | BuyReiteratedEUR 34.10→EUR 30.45 | 11/11/26 | 64.60%Upside | ||
| Leonid TimashevRBC Capital | BuyAssignedEUR 50.14→EUR 44.77 | 11/10/26 | 141.99%Upside | ||
| Edward TenthoffPiper Sandler | BuyReiteratedEUR 57.30 | 11/05/26 | 209.74%Upside | ||
| Ashwani VermaUBS | HoldReiteratedEUR 21.49 | 10/27/26 | 16.15%Upside | ||
| Jessica FyeJ.P. Morgan | HoldReiteratedEUR 31.34→EUR 29.55 | 10/09/26 | 59.71%Upside | ||
| Yaron WerberTD Cowen | HoldAssignedEUR 25.97→EUR 21.49 | 08/12/26 | 16.15%Upside | ||
| Asthika GoonewardeneLeerink Partners | BuyReiteratedEUR 62.67 | 03/13/26 | 238.78%Upside | ||
| James ShinDeutsche Bank | BuyReiteratedEUR 53.72 | 03/09/26 | 190.38%Upside | ||
| Qize DingRothschild & Co Redburn | HoldDowngradedEUR 74.31→EUR 21.49 | 02/12/26 | 16.15%Upside | ||
| Eric Schmidt FCACantor Fitzgerald | BuyReiteratedEUR 67.15→EUR 66.26 | 12/17/25 | 258.14%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Legend Biotech
3 Months
Success Rate8/17 ratings generated profit
47%
Average Return
+3.37%
Copying Edward Tenthoff's trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of +3.37% per trade.
1 Year
Success Rate7/17 ratings generated profit
41%
Average Return
-15.64%
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of -15.64% per trade.
2 Years
Success Rate10/39 ratings generated profit
26%
Average Return
-29.64%
Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 25.64% of your transactions generating a profit, with an average return of -29.64% per trade.
9LB Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 22 | 18 | 15 | 15 | 19 |
| Buy | 2 | 2 | 0 | 0 | 0 |
| Hold | 3 | 5 | 6 | 7 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 27 | 25 | 21 | 22 | 24 |
In the current month, 9LB has received 19 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 9LB average Analyst price target in the past 3 months is 37.87.
9LB Financial Forecast
HighEUR 0.17
ConsensusEUR 0.04
LowEUR 0.00
9LB Earnings Forecast
Next quarter’s earnings estimate for 9LB is EUR 0.04 with a range of EUR 0.00 to EUR 0.17. The previous quarter’s EPS was EUR 0.12. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 378M
ConsensusEUR 341M
LowEUR 329M
9LB Sales Forecast
Next quarter’s sales forecast for 9LB is EUR 340.56M with a range of EUR 329.04M to EUR 377.96M. The previous quarter’s sales results were EUR 322.74M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
9LB Stock Forecast FAQ
What is DE:9LB’s average 12-month price target, according to analysts?
Based on analyst ratings, Legend Biotech’s 12-month average price target is €37.87.
What is DE:9LB’s upside potential, based on the analysts’ average price target?
Legend Biotech has 104.73% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Legend Biotech a Buy, Sell or Hold?
Legend Biotech has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 4 hold ratings and 0 sell ratings.
What is Legend Biotech’s share price target?
The average share price target for Legend Biotech is €37.87. This is based on 10 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €58.20, and the lowest forecast is €21.49. The average share price target represents a 104.73% increase from the current price of €18.5.
What do analysts say about Legend Biotech?
Legend Biotech’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Street analysts.
How can I buy shares of Legend Biotech?
To buy shares of DE:9LB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
